Antimicrobial polymer conjugate containing lysostaphin and polyethylene glycol
AssigneeBiosynexus Incorporated
InventorsScott M. Walsh, Anjali G. Shah, James J. Mond, Andrew Lees, Joseph J. Drabick
Life of this patent
Estimating the term…
Abstract
Water-soluble polymer conjugates of antimicrobial agents retaining at least a portion of the antimicrobial activity of the agent, pharmaceutical compositions containing the polymer conjugates, and methods for treating microbial infections with the pharmaceutical compositions.
Claims26
A composition comprising polyethylene glycol (PEG) conjugated to lysostaphin, wherein said conjugate is a fractionated conjugate consisting essentially of a fraction of lysostaphin conjugated to a single PEG molecule, wherein said lysostaphin retains antimicrobial activity capable of killing live Staphylococcus aureus type 5 in an in vitro killing assay.
A pharmaceutical composition for treating microbial infection comprising polyethylene glycol (PEG) conjugated to lysostaphin, wherein said conjugate is a fractionated conjugate consisting essentially of a fraction of lysostaphin conjugated to a single PEG molecule, wherein said lysostaphin retains antimicrobial activity capable of killing live Staphylococcus aureus type 5 in an in vitro killing assay, and a pharmaceutically acceptable carder.
A method for the prophylactic or therapeutic treatment of a microbial infection in a mammal comprising administering to said mammal a pharmaceutical composition comprising polyethylene glycol (PEG) conjugated to lysostaphin, wherein said conjugate is a fractionated conjugate consisting essentially of a fraction of lysostaphin conjugated to a single PEG molecule, wherein said lysostaphin retains antimicrobial activity capable of killing live Staphylococcus aureus type 5 in an in vitro killing assay, and a pharmaceutically acceptable carrier, in an amount effective for preventing or treating said infection.
Dependencies are inferred from the claim text.